Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Zhendong Chen"'
Autor:
Liang Sun, Zhengyi Wu, Cairong Dong, Shian Yu, He Huang, Zhendong Chen, Zhipeng Wu, Xiangbao Yin
Publikováno v:
BMC Medical Genomics, Vol 16, Iss 1, Pp 1-19 (2023)
Abstract Objective Hepatocellular carcinoma (HCC) immunotherapy is a focus of current research. We established a model that can effectively predict the prognosis and efficacy of HCC immunotherapy by analyzing the immune genes of HCC. Methods Through
Externí odkaz:
https://doaj.org/article/73cfcf9b062d4926831c322bd92e9b9d
Autor:
Lei Zhao, Weiwei Fan, Kunpeng Luo, Siqi Xie, Rui Wang, Jingming Guan, Zhendong Chen, Shizhu Jin
Publikováno v:
Stem Cells International, Vol 2023 (2023)
Background. Colorectal cancer (CRC) is one of the commonest cancers worldwide. As conventional biomarkers cannot clearly define the heterogeneity of CRC, it is essential to establish novel prognostic models. Methods. For the training set, data pertai
Externí odkaz:
https://doaj.org/article/c181213cb4c44946b0d811b29e5c79cb
Autor:
Xiaoyan Chen, Guangze Li, Xingxing Diao, Zitao Guo, Mengling Liu, Jinghua Yu, Qi Huang, Jian Meng, Yaru Xue, Dafang Zhong, Yuandong Zheng, Zhendong Chen, Yali Wu
Publikováno v:
Drug Metabolism and Disposition. 50:809-818
Excretion of [14C]HR011303-derived radioactivity showed significant species difference. Urine (81.50% of dose) was the main excretion route in healthy male subjects, whereas feces (87.16% of dose) was the main excretion route in rats. To further eluc
Autor:
Xiaojing Zhang, Zhiqiang Meng, Shanzhi Gu, Shukui Qin, Zhendong Chen, Xiao Zhang, Linna Wang, Xinni Chen, Jianjun Zou, Ying Liu, Jianping Xiong, Zhenggang Ren
Publikováno v:
International Journal of Cancer. 149:1944-1954
Biliary tract cancer (BTC) is a highly malignant tumor with limited treatment options and poor prognosis. Our study aimed to evaluate camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced BTC. In this multicenter, open-l
Autor:
Jianfeng Zhou, Dong Ma, Hongbing Wang, Qiang Zhang, Changping Wu, Ying Yuan, Lei Yang, Ning Wang, Nong Xu, Zhuang Yu, Rui-Hua Xu, Wei Li, Yongqian Shu, Shubin Wang, Ying Cheng, Jin Li, Weijian Guo, Peiguo Cao, Zhendong Chen, Xiaojun Guo, Sanyuan Sun, Shukui Qin, Weiguo Su, Bin Zhang, Yuxian Bai, Jianming Xu, Hongming Pan, Haihui Chen, Donghui Chen, Tianshu Liu, Jiejun Wang, Yanhong Deng, Lin Shen, Haijun Zhong
Publikováno v:
OncoTargets and Therapy, Vol Volume 14, Pp 4439-4450 (2021)
OncoTargets and therapy
OncoTargets and therapy
Shukui Qin,1 Rui-Hua Xu,2 Lin Shen,3 Jianming Xu,4 Yuxian Bai,5 Lei Yang,6 Yanhong Deng,7 Zhen-dong Chen,8 Haijun Zhong,9 Hongming Pan,10 Weijian Guo,11 Yongqian Shu,12 Ying Yuan,13 Jianfeng Zhou,14 Nong Xu,15 Tianshu Liu,16 Dong Ma,17 Changping Wu,1
Autor:
Quan Liu, M. Bi, Yi Hu, Yan Yu, Helong Zhang, Jianhua Shi, Zhendong Chen, Xiaochun Zhang, Jian Fang, Tianqing Chu, Baohui Han, Kai Li, Jun Lu, Cuicui Han, Wu Zhuang, Xiuwen Wang, Huijuan Wu, Qisen Guo
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 3, Pp 816-824 (2021)
Cancer Biology & Medicine
Cancer Biology & Medicine
Objective: This phase 3 study aimed to test equivalence in efficacy and safety for QL1101, a bevacizumab analogue in Chinese patients with untreated locally advanced non-squamous non-small cell lung cancer (NSCLC). Methods: Eligible patients were ran
Autor:
Chengyou Du, Guoliang Shao, Yajin Chen, Yabing Guo, Jianbing Wu, Aibing Xu, Yuxian Bai, Ming Huang, Baocai Xing, Bixiang Zhang, Tao Yin, Yong Yang, Yan Wang, Yilei Mao, Xuetao Shi, Mingxia Chen, Yinying Lu, Weidong Jia, Zhenggang Ren, Jiuwei Cui, Zhenyuan Gao, Chao Liu, Wei Yang, Yunfeng Shan, Shanzhi Gu, Zhendong Chen, Qiu Li, Yanru Qin, Guowen Yin, Jianming Xu, Jian Wu, Shundong Cang, Feng Xia, Baorui Liu, Junye Wang, Jinhai Wang, Gao-Jun Teng, Hui Zhou, Jia Fan, Zhiqiang Meng
Publikováno v:
The Lancet Oncology. 22:977-990
Summary Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need. The phase
Autor:
Guisheng Li, Qiong Wu, Jin Li, Xiuwen Wang, Yiye Wan, Ying Cheng, Jianping Xiong, Chunhong Hu, Jianqiang Cai, Yong-Qiang Li, Yong Tang, Helong Zhang, Jiang liu, Baoli Qin, Jifeng Feng, Jian Dong, Jianfeng Zhou, Yongqian Shu, Xingwen Li, Jianhong Wang, Yongkun Sun, Minhui Wu, Yigui Chen, Nong Xu, Zhendong Chen, Yuxian Bai, Jufeng Wang, Yanhong Deng, Da Jiang, Yi Ba, Chengxue Dang, Yujuan Qi, Jianming Xu, Donglin Wang, Yihebali Chi
Publikováno v:
Oncologist
Background Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib for patients with refra
Autor:
Zhendong Chen, Hongbing Wang, Shukui Qin, Peiguo Cao, Weiguo Su, Sanyuan Sun, Haihui Chen, Jian Li, Jianfeng Zhou, Haijun Zhong, Yanhong Deng, Rubing Han, Lei Yang, Shubin Wang, Weijian Guo, Donghui Chen, Dong Ma, Xiaojun Guo, Rui-Hua Xu, Wei Li, Zhuang Yu, Ying Cheng, Tianshu Liu, Jin Li, Yongqian Shu, Bin Zhang, Jiejun Wang, Hongming Pan, Jianming Xu, Yuxian Bai, Ning Wang, Nong Xu, Changping Wu, Ying Yuan
Publikováno v:
Future Oncology. 17:1339-1350
Background: FRESCO study demonstrated efficacy and safety of fruquintinib in metastatic colorectal cancer patients. Impact of prior targeted therapy (PTT) on efficacy and safety of fruquintinib was evaluated. Materials & methods: In this subgroup ana
Autor:
Jonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay V Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares, Nataliia Voitko, Andrzej Kazarnowicz, Mustafa Özgüroglu, Nikolay Conev, Maximilian Hochmair, Otto Burghuber, Irfan Çiçin, Vladimir Moiseenko, Mustafa Erman, Dariusz Kowalski, Marek Wojtukiewicz, Hryhoriy Adamchuk, Alexander Vasilyev, Serhii Shevnia, Spartak Valev, Maria Amelia Insa Molla, Grygorii Ursol, Anne Chiang, Sylvia Hartl, Zsolt Horváth, Gábor Pajkos, Sang-We Kim, Alexey Smolin, Tuncay Göksel, Shaker Dakhil, Jaromir Roubec, Krisztina Bogos, Robin Cornelissen, Jong-Seok Lee, Maria Rosario Garcia Campelo, Marta Lopez Brea, Ahmet Alacacioglu, Ignacio Casarini, Rumyana Ilieva, Ivan Tonev, Attila Somfay, Jair Bar, Alona Zer Kuch, Mauro Minelli, Roberta Bartolucci, Fausto Roila, Haruhiro Saito, Koichi Azuma, Gyeong-Won Lee, Alexander Luft, Michal Urda, Juan Ignacio Delgado Mingorance, Margarita Majem Tarruella, David Spigel, Krassimir Koynov, Milada Zemanova, Jens Panse, Christian Schulz, Zsolt Pápai Székely, Veronika Sárosi, Angelo Delmonte, Anna Cecilia Bettini, Makoto Nishio, Isamu Okamoto, Lizza Hendriks, Slawomir Mandziuk, Yun Gyoo Lee, Lyubov Vladimirova, Dolores Isla Casado, Manuel Domine Gomez, Alejandro Navarro Mendivil, Teresa Morán Bueno, Shang-Yin Wu, Jeanna Knoble, Jana Skrickova, Violetka Venkova, Werner Hilgers, Eckart Laack, Helge Bischoff, Andrea Fülöp, Ibolya Laczó, Judit Kósa, András Telekes, Tatsuya Yoshida, Shintaro Kanda, Toyoaki Hida, Hidetoshi Hayashi, Tadashi Maeda, Tetsuji Kawamura, Yasuharu Nakahara, Niels Claessens, Ki Hyeong Lee, Chao-Hua Chiu, Sheng-Hao Lin, Chien-Te Li, Ahmet Demirkazik, Eric Schaefer, Petros Nikolinakos, Jeffrey Schneider, Sunil Babu, Bernd Lamprecht, Michael Studnicka, Carlos Fausto Nino Gorini, Juraj Kultan, Vitezslav Kolek, Pierre-Jean Souquet, Denis Moro-Sibilot, Maya Gottfried, Egbert Smit, Kyung Hee Lee, Peter Kasan, Jozef Chovanec, Olexandr Goloborodko, Oleksii Kolesnik, Yuriy Ostapenko, Shailendra Lakhanpal, Basir Haque, Winston Chua, Joseph Stilwill, Susana Noemi Sena, Gustavo Colagiovanni Girotto, Pedro Rafael Martins De Marchi, Fabricio Augusto Martinelli de Oliveira, Pedro Dos Reis, Rositsa Krasteva, Yanqiu Zhao, Chengshui Chen, Leona Koubkova, Gilles Robinet, Christos Chouaid, Christian Grohe, Jürgen Alt, Eszter Csánky, Éva Somogyiné Ezer, Norman Isaac Heching, Young Hak Kim, Shinji Aatagi, Shoichi Kuyama, Daijiro Harada, Naoyuki Nogami, Hiroshi Nokihara, Hisatsugu Goto, Agnes Staal van den Brekel, Eun Kyung Cho, Joo-Hang Kim, Doina Ganea, Tudor Ciuleanu, Ekaterina Popova, Dina Sakaeva, Marian Stresko, Pavol Demo, Robert Godal, Yu-Feng Wei, Yen-Hsun Chen, Te-Chun Hsia, Kang-Yun Lee, Huang-Chih Chang, Chin-Chou Wang, Afshin Dowlati, Christopher Sumey, Steven Powell, Jonathan Goldman, Juan Jose Zarba, Emilio Batagelj, Andrea Viviana Pastor, Mauro Zukin, Clarissa Serodio da Rocha Baldotto, Luis Alberto Schlittler, Aknar Calabrich, Claudia Sette, Asen Dudov, Caicun Zhou, Hervé Lena, Susanne Lang, Zsuzsanna Pápai, Koichi Goto, Shigeki Umemura, Kenya Kanazawa, Yu Hara, Masahiro Shinoda, Masahiro Morise, Jeroen Hiltermann, Robert Mróz, Andrei Ungureanu, Igor Andrasina, Gee-Chen Chang, Ihor Vynnychenko, Yaroslav Shparyk, Anna Kryzhanivska, Helen Ross, Kailhong Mi, Rodney Jamil, Michael Williamson, Joseph Spahr, Zhigang Han, Mengzhao Wang, Zhixiong Yang, Jie Hu, Wei Li, Jun Zhao, Jifeng Feng, Shenglin Ma, Xiangdong Zhou, Zongan Liang, Yi Hu, Yuan Chen, Minghong Bi, Yongqian Shu, Kejun Nan, Jianying Zhou, Wei Zhang, Rui Ma, Nong Yang, Zhong Lin, Gang Wu, Jian Fang, Helong Zhang, Kai Wang, Zhendong Chen
Publikováno v:
The Lancet Oncology, 22(1), 51-65. Lancet Publishing Group
Background: First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus platinum–etoposide alone in patients with extensive-stage small-cell lung cance